Procter & Gamble Health Limited (PGHL) - Total Liabilities
Based on the latest financial reports, Procter & Gamble Health Limited (PGHL) has total liabilities worth Rs2.75 Billion INR (≈ $29.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Procter & Gamble Health Limited to track the company's year-over-year net asset growth rate.
Procter & Gamble Health Limited - Total Liabilities Trend (2003–2024)
This chart illustrates how Procter & Gamble Health Limited's total liabilities have evolved over time, based on quarterly financial data. See Procter & Gamble Health Limited (PGHL) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Procter & Gamble Health Limited Competitors by Total Liabilities
The table below lists competitors of Procter & Gamble Health Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inno Laser Technology Co. Ltd.
SHE:301021
|
China | CN¥184.04 Million |
|
Qingdao Yunlu Advanced Materials Technology Co. Ltd. A
SHG:688190
|
China | CN¥719.01 Million |
|
Delta Galil Industries Ltd
TA:DELT
|
Israel | ILA1.18 Billion |
|
Pabrik Kertas Tjiwi Kimia Tbk
JK:TKIM
|
Indonesia | Rp988.48 Million |
|
Kunshan Huguang Auto Harness Co Ltd
SHG:605333
|
China | CN¥4.82 Billion |
|
Gosuncn Technology Group Co Ltd Class A
SHE:300098
|
China | CN¥2.29 Billion |
|
Wuxi Boton Technology Co Ltd
SHE:300031
|
China | CN¥2.15 Billion |
|
Deluxe Corporation
NYSE:DLX
|
USA | $1.86 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Procter & Gamble Health Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PGHL market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.26 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Procter & Gamble Health Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Procter & Gamble Health Limited (2003–2024)
The table below shows the annual total liabilities of Procter & Gamble Health Limited from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Rs2.57 Billion ≈ $27.82 Million |
+0.44% |
| 2023-12-31 | Rs2.56 Billion ≈ $27.70 Million |
-26.89% |
| 2022-12-31 | Rs3.50 Billion ≈ $37.88 Million |
+26.36% |
| 2021-12-31 | Rs2.77 Billion ≈ $29.98 Million |
-1.85% |
| 2020-12-31 | Rs2.82 Billion ≈ $30.55 Million |
+4.60% |
| 2019-12-31 | Rs2.70 Billion ≈ $29.20 Million |
+23.11% |
| 2018-12-31 | Rs2.19 Billion ≈ $23.72 Million |
-14.97% |
| 2017-12-31 | Rs2.58 Billion ≈ $27.90 Million |
+8.67% |
| 2016-12-31 | Rs2.37 Billion ≈ $25.67 Million |
+23.36% |
| 2015-12-31 | Rs1.92 Billion ≈ $20.81 Million |
+25.01% |
| 2014-12-31 | Rs1.54 Billion ≈ $16.65 Million |
+22.57% |
| 2013-12-31 | Rs1.26 Billion ≈ $13.58 Million |
+13.53% |
| 2012-12-31 | Rs1.11 Billion ≈ $11.96 Million |
+23.53% |
| 2011-12-31 | Rs895.40 Million ≈ $9.68 Million |
+7.16% |
| 2010-12-31 | Rs835.60 Million ≈ $9.04 Million |
-17.16% |
| 2009-12-31 | Rs1.01 Billion ≈ $10.91 Million |
-7.58% |
| 2008-12-31 | Rs1.09 Billion ≈ $11.80 Million |
+63.80% |
| 2007-12-31 | Rs666.30 Million ≈ $7.21 Million |
-22.82% |
| 2006-12-31 | Rs863.30 Million ≈ $9.34 Million |
-3.30% |
| 2005-12-31 | Rs892.80 Million ≈ $9.66 Million |
+13.29% |
| 2004-12-31 | Rs788.10 Million ≈ $8.52 Million |
-3.66% |
| 2003-12-31 | Rs818.00 Million ≈ $8.85 Million |
-- |
About Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter … Read more